An infant formula containing dairy lipids increased red blood cell membrane Omega 3 fatty acids in 4&#160;month-old healthy newborns: a randomized controlled trial by M.L. Gianni et al.
RESEARCH ARTICLE Open Access
An infant formula containing dairy lipids
increased red blood cell membrane Omega
3 fatty acids in 4 month-old healthy
newborns: a randomized controlled trial
Maria Lorella Gianni1, Paola Roggero1, Charlotte Baudry2*, Catherine Fressange-Mazda3, Claudio Galli4ˆ,
Carlo Agostoni5, Pascale le Ruyet2 and Fabio Mosca1
Abstract
Background: When breastfeeding is not possible, infants are fed formulas (IF) in which lipids are usually of plant
origin. However, the use of dairy fat in combination with plant oils enables a lipid profile closer to breast milk in
terms of fatty acid (FA) composition, triglyceride structure, polar lipids and cholesterol contents. The objective of
this study was to determine the effect of an IF containing a mix of dairy fat and plant oils on Omega-3 FA content
in red blood cells (RBC).
Methods: This study was a monocentric, double-blind, controlled, randomized trial. Healthy term infants were fed
formulas containing a mix of dairy fat and plant oils (D), plant oils (P) or plant oils supplemented with ARA and
DHA (PDHA). Breastfed infants were enrolled as a reference group (BF). FA in RBC phosphatidylethanolamine was
evaluated after 4 months and FA in whole blood were evaluated at enrollment and after 4 months by gas
chromatography. Differences between groups were assessed using an analysis of covariance with sex and
gestational age as covariates.
Results: Seventy IF-fed and nineteen BF infants completed the protocol. At 4 months, RBC total Omega-3 FA levels
in infants fed formula D were significantly higher than in group P and similar to those in groups PDHA and BF. RBC
DHA levels in group D were also higher than in group P but lower than in groups PDHA and BF. RBC n-3 DPA
levels in group D were higher than in groups P, PDHA and BF. A decrease in proportions of Omega-3 FA in whole
blood was observed in all groups.
Conclusions: A formula containing a mix of dairy lipids and plant oils increased the endogenous conversion of
Omega-3 long-chain FA from precursor, leading to higher total Omega-3, DPA and DHA status in RBC than a plant
oil-based formula. Modifying lipid quality in IF by adding dairy lipids should be considered as an interesting
method to improve Omega-3 FA status.
Trial registration: Identifier NCT01611649, retrospectively registered on May 25, 2012.
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Background
Breast milk is considered by the World Health
Organization (WHO) as the optimal form of nourish-
ment for infants up to 6 months. Lipids are major com-
ponents in human milk, providing approximately 50% of
total dietary energy. Triacylglycerols in human milk have
a specific fatty acid (FA) composition, which can be in-
fluenced by maternal dietary habits or by lactation
stages. Proportions of saturated and monounsaturated
FA are relatively stable whereas proportions of polyun-
saturated FA (PUFA) can vary more widely [1]. Among
PUFA, human milk provides alpha-linolenic (ALA) and
linoleic acids (LA) which are essential fatty acids (EFA).
They can be endogenously converted by the newborn
into long-chain derivatives of Omega 3 and Omega 6
families, such as docosahexaenoic acid (DHA) and ara-
chidonic acid (ARA), respectively. However, this conver-
sion is considered to be low in humans [2]. Human milk
also contains preformed long-chain PUFA (LCPUFA) of
both series with DHA representing 0.1–1% of total FA
and ARA 0.4–0.9% of total FA [1]. LCPUFA accumula-
tion is very important during both the fetal and postna-
tal periods in brain and retina [3]. Consequently,
bioavailability of ALA, LA, DHA and ARA from breast
milk or infant formulas is critical in early life to sustain
optimal visual and brain development of the newborn
and later-life cognitive functions [4].
Fat sources used in most infant formulas currently mar-
keted are blends of plant oils used to match the FA profile
found in human milk. Indeed, since the middle of 20th
century, infant formulas have been enriched in EFA-rich
plant oils and bovine milk fat has been progressively
removed [1]. Infant formulas can also be optionally sup-
plemented with fish, algae or fungus oils providing pre-
formed DHA and ARA. However, lipids of plant oils are
not comparable to lipids of human milk in terms of FA di-
versity, triacylglycerol structure, fat globule composition,
complex lipids and cholesterol contents. Although not
containing high levels of LCPUFA, the use of dairy lipids
in combination with plant oils could provide a lipid com-
position and structure closer to human milk, thus improv-
ing the quality of infant formula fat profile. Indeed, infant
formulas provide milk-specific FA and cholesterol only
when dairy lipids are used as a fat source in combination
with plant oils [1]. Short and medium chain FA, lauric
acid, myristic acid and palmitic acid contents in formulas
can vary considerably according to the use of palm oil,
coconut oil or dairy lipids [1]. Moreover, plant oils do not
encounter the specific triglyceride structure with palmitic
acid in sn2 position found in breast milk (60–85% of sn2-
palmitate) or cow’s milk (more than 45%). Therefore, it
has been shown that formulas with only plant oils as
sources of lipids had less than 15% of palmitic acid in sn2
position whereas formulas containing a blend of dairy
lipids and plant oils had 48% of palmitic acid in sn2 pos-
ition [5]. This triglyceride structure is of particular import-
ance because long-chain saturated FA in the sn2 position
are more efficiently digested and absorbed [6].
Dairy lipids specifically contain about 10% of myr-
istic acid and 10% of short and medium chain FA
(C4-C10) while plant oils provide much less of these
FA. Short-chain FA represent a rapid source of energy
for the infant, because they enter directly the portal
vein and are known to be completely absorbed and
metabolized. Myristic and short/medium chain FA
could also increase bioavailability and conversion of
n-3 PUFA as demonstrated in vitro [7]. Furthermore,
benefits of dairy lipids on the conversion of Omega 3
precursor to long-chain derivatives have been de-
scribed in several studies. Indeed, in adults, a moder-
ate intake of dairy lipids and rapeseed oil improved
plasma DHA levels and blood fluidity [8, 9]. In
Omega 3-deficient rats, it has been demonstrated that
for a similar ALA content, a blend of dairy lipids and
rapeseed oil induced a higher level of brain DHA
than a blend of plant oils even if supplemented with
preformed DHA [10, 11]. In mice, a diet containing a
blend with dairy lipids given from the first day of
gestation until adulthood increased DHA levels and
neuroplasticity in the brain of the offspring compared
with a diet containing only plant oils [12]. In the
same mouse model, it has been also demonstrated
that a diet containing dairy lipids protected from the
adverse effects induced by an early life inflammatory
event on neurogenesis and adult spatial memory [13].
Consequently, these data suggest that the use of dairy
lipids in combination with plant oils could potentially
improve long-chain Omega 3 status and promote the
accretion of DHA in the developing brain.
The aim of the present study was to assess the
impact of an infant formula containing dairy lipids
and plant oils on FA composition in RBC and whole
blood, especially on Omega 3 FA content, in
4 month-old healthy infants.
Methods
Study design
This monocentric, double-blind, controlled, random-
ized trial was conducted in 2012–2013 in the Depart-
ment of Neonatology of the Fondazione IRCCS Cà
Granda Ospedale Maggiore Policlinico, Milano, Italy
(NCT01611649). The study was approved by the local
Ethical Committee and conducted in accordance with
Good Clinical Practice and the principles and rules of
the Declaration of Helsinki. Parents or legal caregivers
provided written informed consent prior to enroll-
ment of their infants in the study. The study protocol
has been previously published [14].
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Population
Healthy full-term infants born in the Department of Neo-
natology were screened for participation in the study.
When breastfeeding was not possible (contraindication or
mothers not intended to breastfeed), infants were ran-
domly allocated to be fed for 4 months with a formula
containing either: a mix of plant oils and dairy fat (D),
only plant oils (P) or plant oils supplemented with ARA
and DHA (PDHA). Infants whose mothers intended to ex-
clusively breastfeed from birth through at least 4 months
were enrolled in a nonrandomized reference group (BF).
Inclusion criteria were: gestational age 37 to 42 weeks,
birth weight > 2500 g, healthy newborns from normal
pregnancy, aged up to 3 weeks when entering the study,
no breastfeeding (for the formula-fed groups) or exclusive
breastfeeding (for the reference group). Exclusion criteria
were: positive family history of allergy to milk proteins,
known congenital or postnatal diseases which could inter-
fere with the study and newborns whose parents had
planned to move within 6 months after birth.
Study formulas
Study formulas were formulated into powders and were
reconstituted at 13.3%. They were manufactured and pro-
vided by Milumel®, Lactalis, Craon, France. The 3 tested
formulas were packaged in blinded containers labeled only
with study details and number of randomization; they
were indistinguishable in appearance and texture. Both
the investigators and the infants’ parents were blind to the
group allocation. The randomization schedule was
computer-generated and stratified on sex. Compositions
of the 3 study formulas were in compliance with the
European Directive 2006/141/EC on infant formulas and
are detailed in Table 1. The 3 formulas had similar energy
and macronutrient contents but they differed by the na-
ture of their lipid sources. Formula D contained a mixture
of dairy lipids and plant oils (rapeseed, sunflower, high
oleic sunflower); formula P contained only plant oils
(palm, rapeseed, sunflower) and formula PDHA contained
plant oils (palm, rapeseed, sunflower) supplemented with
ARA (0.4%) and DHA (0.2%). Study formulas were con-
sumed straightaway after randomization and were pro-
vided for the 4 subsequent months.
Objectives and outcomes
The main objective of this study was to investigate the
effect of formula D on the RBC membrane total Omega
3 FA content as compared to formulas P and PDHA and
to BF reference group. Total Omega 3 FA levels included
ALA, EPA (eicosapentaenoic acid, 20:5n-3), DPA (doco-
sapentaenoic acid, 22:5n-3) and DHA levels. The sec-
ondary objective was to evaluate changes between
4 months and enrollment in whole blood FA contents in
infants consuming formula D in comparison to formula
P and PDHA and BF. Impact of formulas on growth,
body composition and gastrointestinal tolerance was also
investigated but these data are under publication in an-
other article.
Measurement of FA levels in RBC membrane
Venous blood samples were drawn after consumption of
the allocated formula or breastfeeding for 4 months. Blood
was collected on heparin. Plasma was separated by 15-min
centrifugation (2200 g at 4 °C) from RBC that were rinsed
with saline solution (NaCl 0.9%). Plasma and RBC were
stored at − 80 °C for later analysis. RBC total lipids were
extracted and phosphatidylethanolamine (PE) was isolated
from other phospholipids by thin layer chromatography.
FA levels of RBC PE were measured by means of a gas–li-
quid chromatography (HPLC) by ITERG, Pessac, France.
Results are expressed as percentage of total FA.
Measurement of blood FA levels
Whole blood samples were collected using a heel stick
at enrollment and after 4 months of consumption of the
allocated formula or breastfeeding. FA levels were quan-
tified by means of a gas–liquid chromatography (HPLC)
by Oxigenlab, Brescia, Italy. Results are expressed as per-
centage of total FA.
Table 1 Composition of study formulas
Formula D Formula P Formula PDHA
100 mla 100 mla 100 mla
Energy kJ 275 275 275
kcal 66 66 66
Protein g 1.3 1.3 1.3
Carbohydrates g 8.1 8.1 8.1
Lactose g 6.8 6.8 6.8
Fat g 3.1 3.1 3.1
LA mg 439 549 549
% TFA 14.2 17.7 17.7
ALA mg 73 55 55
% TFA 2.3 1.8 1.8
Ratio LA/ALA 6 10 10
ARA mg ≤ 0.1 12.4
% TFA 0.4
DHA mg 6.2
% TFA 0.2
Ratio ARA/DHA 2
Composition of tested formulas according to manufacturer data. Formula D
contained a mixture of dairy lipids (cream) and plant oils (rapeseed, sunflower
and high oleic sunflower); formula P contained only plant oils (palm, rapeseed,
sunflower) and formula PDHA contained plant oils (palm, rapeseed, sunflower)
supplemented with ARA and DHA)
LA linoleic acid, ALA alpha-linolenic acid, ARA arachidonic acid, DHA docosahexaenoic
acid, TFA total fatty acids
aReconstituted 13.3%
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Sample size
Calculation of sample size for this study has been previ-
ously detailed [14]. In order to detect a difference of
20% in the RBC membrane Omega 3 FA levels (basal
value of 7.3% and standard deviation of 1.3 [15]) be-
tween infants receiving formula D and infants receiving
formula P or formula PDHA, at a power of 90% and
with an alpha error of 5%, a total of 17 infants per group
was necessary. To take into account the multiplicity of
comparisons, the calculation was done with an alpha
error of 2.5% and a total of 21 infants per group was
needed. Considering dropouts, a total of 30 infants per
group were enrolled.
Statistical analyses
Statistical analyses were performed using SAS software
(SAS Institute Inc., Cary NC, USA) by Soladis, Lyon,
France. Continuous variables were expressed as mean
and standard deviation. Differences among groups for
FA levels were analyzed with an analysis of variance
with 3 fixed factors (group, sex, gestational age). Pair-
wise comparisons were made using post-hoc Tukey’s
test for multiple comparisons. A p-value < 0.05 was
considered significant.
Results
Study population
A total of 117 healthy newborns were enrolled. Of these,
88 were randomized to the formula-fed groups and 29
were enrolled in the breastfed reference group (Fig. 1). A
total of 18 (20%) infants from the formula groups and 10
(34%) in the breastfed group withdrew before the end of
the study (Fig. 1). Rates of discontinuation were similar
in the 3 formula groups (23% in formula D and PDHA;
14% in formula P). Gastrointestinal symptoms (ie. regur-
gitations, reflux, constipation, colic and flatulence) were
the most common reason for study discontinuation in
the 3 formula groups: 57% in group D, 75% in group P
and 43% in group PDHA. Among the breastfed group, 8
babies were lost to follow-up and breastfeeding was
stopped before the next visit for 2 babies.
Baseline characteristics in each group are presented
in Table 2. Proportion of boys was similar in the 3 for-
mula groups (53–57%) and was of 38% in the breastfed
reference group (Table 2). A high proportion of caesar-
ean births (43–64%) was observed in all groups without
any difference between groups (Table 2). Gestational
age was around 38 weeks in the 3 formula groups and
around 39 weeks in the breastfed group. On average,
infants were enrolled in the study at 5–10 days of life
(Table 2). At baseline, weight in group P was signifi-
cantly lower than in breastfed infants (p = 0.015)
(Table 2). Height, head circumference and body com-
position were similar in the 4 groups at baseline (all
p > 0.05) (Table 2). Total Omega 3 and DHA levels in
whole blood were similar in the 4 groups at baseline,
despite a tendency for higher DHA levels in the BF
group but not statistically significant (Table 2).
Mean daily volume of formula consumed was evalu-
ated during a 2 day-period at 1 month and 3 months.
Most of formula-fed infants consumed more than
600 ml daily at 1 month (around 95% of infants) and
more than 700 ml daily at 3 months (around 82%). No
significant differences in formula intake were observed
among the 3 formula groups at 1 month (p = 0.980) or
at 3 months (p = 0.177).
RBC membrane FA levels after 4 months
Primary endpoint was total Omega 3 FA levels in PE of
RBC membrane after 4 months (Fig. 2). RBC total Omega
3 FA levels were significantly higher in infants fed with for-
mula D (8.6 ± 1.2% TFA) than with formula P (5.7 ± 0.8%
Fig. 1 Flow of study subjects. Formula D contained a mixture of dairy lipids and plant oils; formula P contained only plant oils and
formula PDHA contained plant oils supplemented with ARA and DHA. GI (gastrointestinal) symptoms included regurgitation, reflux,
constipation, colic and flatulence
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TFA; p < 0.001) but similar to those of infants fed with for-
mula PDHA (8.8 ± 1.1% TFA; p = 0.956) or BF (9.7 ± 1.8%
TFA; p = 0.191) (Fig. 2). Sum of DHA and n-3 DPA levels
accounts for more than 90% of RBC total Omega 3. DHA
levels in group D (4.1 ± 0.8% TFA) were significantly higher
than in group P (3.4 ± 0.7% TFA; p = 0.029) but lower than
in groups PDHA (6.8 ± 1.0% TFA) and BF (7.0 ± 1.4% TFA;
both p < 0.001) (Fig. 2). n-3 DPA levels in group D (3.6 ±
0.6% TFA) were higher than in all the other groups (P: 1.9
± 0.3; PDHA: 1.6 ± 0.2; BF: 2.2 ± 0.5% TFA; p < 0.001 for
all) (Fig. 2). In group PDHA, total Omega 3 and DHA
levels were similar to breastfed but n-3 DPA levels were sig-
nificantly lower (p < 0.001).
When the BF group was excluded from the
statistical comparison, results were similar with
significantly higher levels of total Omega 3 and DHA
in group D than in group P (p < 0.001 and p =
0.006, respectively).
RBC membrane compositions for the other FA are
presented in Table 3. Total saturated FA were similar in
the 3 formula groups. Percentage of MUFA was signifi-
cantly higher in formula D-fed infants than in formula
PDHA (p < 0.001) and BF (p = 0.034) (Table 3). Total
Omega 6 and ARA levels were similar in the 3 formula
groups and breastfed BF (Table 3). However, LA levels
in formula D-fed infants were similar to formula P-fed
(p = 0.630) but higher than in formula PDHA-fed
(p < 0.001) and BF (p < 0.001). ALA and EPA levels in
formula D-fed infants were significantly higher than in
the other groups (all p < 0.05).
Table 2 Infants’ characteristics at enrollment
Formula D Formula P Formula PDHA Breastfed p-value
n = 30 n = 28 n = 30 n = 29
Sex, no. (%)
Girls 13 (43.3) 11 (39.3) 14 (46.7) 18 (62.1) 0.329
Boys 17 (56.7) 17 (60.7) 16 (53.3) 11 (37.9)
Delivery mode, no. (%)
Natural 11 (36.7) 10 (35.7) 17 (56.7) 14 (48.3) 0.310
Caesarean 19 (63.3) 18 (64.3) 13 (43.3) 15 (51.7)
Gestational age, weeks, mean (SD) 38.4 (1.2) 38.4 (1.1) 38.3 (1.0) 39.0 (1.0) 0.072
Age at enrollment, days, mean (SD) 6.8 (5.6) 4.9 (4.5) 9.6 (7.9) 8.8 (6.6) 0.076
Weight, g, mean (SD) 3144.2 (448.6) 2942.9 (386.6)X 3156.4 (431.8) 3308.7 (533.9) 0.029
Height, cm, mean (SD) 49.1 (2.2) 48.9 (2.2) 49.7 (1.9) 50.1 (1.8) 0.112
Head circumference, cm, mean (SD) 34.4 (1.2) 34.3 (1.4) 34.7 (1.4) 35.3 (2.0) 0.068
Fat mass, % BW, mean (SD) 10.3 (2.9) 10.8 (3.4) 9.8 (3.5) 11.6 (5.4) 0.321
Total Omega 3 in whole blood, %, mean (SD) 12.9 (3.1) 14.2 (3.6) 13.2 (4.2) 15.0 (4.3) 0.384
DHA in whole blood, %, mean (SD) 3.2 (1.1) 3.6 (1.1) 3.4 (0.9) 4.1 (1.8) 0.057
Formula D contained a mixture of dairy lipids and plant oils; formula P contained only plant oils and formula PDHA contained plant oils supplemented with ARA
and DHA. BW: body weight. Comparison of the 4 groups by ANOVA 1 fixed factor (Group) and post-hoc Tukey’s adjustments
Xp < 0.05 vs. BF
Fig. 2 Total Omega 3, DHA and DPA levels (% of total FA) in PE of RBC membrane after 4 months. Formula D (n = 23) contained a mixture of
dairy lipids and plant oils; formula P (n = 24) contained only plant oils and formula PDHA (n = 23) contained plant oils supplemented with ARA
and DHA. BF: breastfed reference group (n = 18). PE: phosphatidylethanolamine. Comparison of the 4 groups by ANOVA with 3 fixed factors (Sex,
gestational age, group) and post-hoc Tukey’s adjustments. a≠ b ≠ c; p < 0.05
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Changes in whole blood FA levels between enrollment
and 4 months
Changes of total Omega 3 and DHA levels (expressed
as deltas) in whole blood between 4 months and en-
rollment are presented in Fig. 3. Percentage of total
Omega 3 significantly decreased between 4 months
and enrollment in all groups (Fig. 3). The decrease in
percentage of Omega 3 in group D (− 6.1 ± 4.4% TFA)
was similar to those in group P (− 9.2 ± 4.3% TFA;
p = 0.087), PDHA (− 3.5 ± 4.2% TFA; p = 0.144) and
BF (− 5.2 ± 4.7% TFA; p = 0.847) (Fig. 3). However,
this decrease was significantly higher in group P than
in group PDHA (p < 0.001) and BF (p = 0.15) (Fig. 3).
Proportions of DHA in whole blood also decreased
with time in all groups (Fig. 3). The decrease in DHA
observed in group D (− 1.8 ± 1.2% TFA) was similar
to those in group P (− 2.5 ± 1.2% TFA; p = 0.388) and
BF (− 1.4 ± 1.9% TFA; p = 0.639) but higher than in
group PDHA (− 0.4 ± 0.8% TFA; p < 0.001) (Fig. 3). n-
3 DPA levels were not evaluated in whole blood.
Discussion
This study demonstrated that 4-month consumption of a
formula containing dairy lipids was associated with a higher
total Omega 3 level in RBC membrane compared with a
formula containing only lipids of plant origin in healthy in-
fants. Total Omega 3 levels reached with a formula con-
taining dairy lipids were similar to those of infants fed with
a formula supplemented with DHA and to breastfed in-
fants. Although breast milk remains the best nutritional
choice for infants, the results of this study suggest that dairy
Table 3 RBC membrane FA levels (% of total FA) after 4 months
Formula D
n = 23
Formula P
n = 24
Formula PDHA
n = 23
BF
n = 18
p-value
Total SFA 33.4 ± 3.1 34.1 ± 3.6 35.2 ± 2.5 34.7 ± 2.9 0.514
Total MUFA 22.4 ± 2.1a 21.5 ± 1.5a, b 20.2 ± 1.4b 21.0 ± 2.1b < 0.001
Total PUFA 43.7 ± 3.6 44.1 ± 3.7 44.3 ± 2.5 43.9 ± 3.5 0.342
Total Omega 6 35.0 ± 2.7 38.3 ± 3.3 35.4 ± 1.8 34.0 ± 2.5 0.465
18:2(n-6) LA 6.2 ± 0.6a 6.3 ± 0.6a 4.4 ± 0.4b 3.8 ± 0.8c < 0.001
20:4(n-6) ARA 20.3 ± 1.9 21.6 ± 2.2 22.6 ± 1.5 22.2 ± 1.7 0.747
22:4(n-6) 5.9 ± 1.1 6.9 ± 1.3 6.2 ± 1.1 5.6 ± 1.5 0.261
22:5(n-6) DPA n-6 0.8 ± 0.2 1.1 ± 0.3 0.9 ± 0.2 0.9 ± 0.3 0.359
18:3(n-3) ALA 0.2 ± 0.0a 0.1 ± 0.0b 0.1 ± 0.0b 0.1 ± 0.1b < 0.001
20:5(n-3) EPA 0.7 ± 0.2a 0.3 ± 0.1b 0.4 ± 0.1c 0.5 ± 0.1c < 0.001
Formula D (n = 23) contained a mixture of dairy lipids and plant oils; formula P (n = 24) contained only plant oils and formula PDHA (n = 23) contained plant oils
supplemented with ARA and DHA. BF: breastfed reference group (n = 18). PE: phosphatidylethanolamine
Comparison of the 4 groups by ANOVA with 3 fixed factors (Sex, gestational age, group) and post-hoc Tukey’s adjustments
a ≠ b ≠ c; p < 0.05
Fig. 3 Changes in total Omega 3 and DHA levels in whole blood between 4 months and enrollment expressed as deltas (% of total FA). Formula
D (n = 23) contained a mixture of dairy lipids and plant oils; formula P (n = 24) contained only plant oils and formula PDHA (n = 23) contained
plant oils supplemented with ARA and DHA. BF: breastfed reference group (n = 18). Comparison of the 4 groups by ANOVA with 3 fixed factors
(Sex, gestational age, group) and post-hoc Tukey’s adjustments. a ≠ b≠ c; p < 0.05
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lipids in infant formulas could stimulate the conversion of
Omega 3 FA precursors into long-chain derivatives.
The beneficial effects of dairy lipids on Omega 3 FA con-
version have already been described in previous studies in
humans [8, 9] or animal models [10–12]. These effects of
dairy lipids could be due to several mechanisms resulting
from the specific FA composition of dairy fat. Firstly, dairy
fat contains high proportions of short and medium chain
FA, which are highly oxidized after absorption. Therefore,
they may spare ALA from oxidation and consequently
favor its partitioning towards desaturation and elongation
pathways to form long-chain derivatives. Another mechan-
ism to explain the effects of dairy fat could be a selective
gene or post-traductional activation of desaturases and
elongases which are the enzymes involved in n-3 conver-
sion. In particular, the dairy lipid-based formula had a
higher content of myristic acid than plant oil-based formu-
las and this FA has been shown to increase delta 6 desatur-
ase activity in vitro [7]. However, these hypothesis would
need to be demonstrated.
One limitation of this study was that formulas slightly
differed by their LA and ALA contents and by their LA
to ALA ratio, which was lower in the formula with dairy
lipid (around 6:1) than in formulas with only plant oils
(around 10:1). The n-6 to n-3 ratio has been recognized
as an important factor driving the conversion of ALA to
long-chain derivatives because of the competition be-
tween LA and ALA for their desaturation and elongation
pathways. This could partly explain the increase in RBC
total Omega 3 FA observed with the dairy lipid-based
formula. However, previous data in rats showed benefits
of dairy lipids versus plant oils on RBC composition and
brain DHA accretion for similar ALA contents and LA
to ALA ratios in the diets [11].
In this study, the increase in RBC total Omega 3 levels
with the dairy lipid-based formula resulted from an in-
crease in all the n-3 FA, with n-3 DPA and DHA repre-
senting more than 90% of total Omega 3 in RBC. RBC
DHA level after 4 months was higher in infants fed the
formula containing dairy lipids than in those fed the for-
mula with only plant oils but remained lower than in in-
fants fed with preformed DHA (formula or breastfed
infants). RBC membrane DHA levels in infants fed with
a formula supplemented with DHA were significantly
higher than those observed in infants fed the similar for-
mula without DHA, suggesting that RBC DHA levels are
strongly influenced by the DHA supplementation, as
already described in previous studies [16–18].
Results of FA compositions in whole blood showed a
decrease in proportions of total Omega 3 and DHA be-
tween 4 months and enrollment in all groups, but it was
more pronounced in infants fed formula with only vege-
table lipids. These results are in concordance with those
reported in a previous study showing that the largest
postnatal decline in DHA was observed in infants fed
nonsupplemented formula [19].
RBC n-3 DPA was the main FA affected by dairy lipids
and was increased by 90% compared with the plant oil-
based formula while DHA was only increased by 22%. The
literature on n-3 DPA is quite limited but available data
suggests beneficial health effects of this FA [20]. The pref-
erential accumulation of n-3 DPA in RBC observed in this
study could be due to a limited rate of the conversion of n-
3 DPA to DHA, mainly in liver, as shown by in vivo studies
[20]. On the other hand, n-3 DPA might represent the pre-
ferred form of incorporation of n-3 long chain FA in RBC.
Indeed, ALA can be elongated and desaturated in a tissue-
dependent manner, with a tissue-selective accumulation of
its derivatives [21]. For example, in ALA-fed rats, an in-
crease in ALA, EPA and DPA was observed in plasma, liver
and heart while an increase in DPA and DHA occurred in
the brain [21]. Also, in neonatal baboons who received an
oral dose of labeled ALA at 4 weeks of age, the distribution
of labeled FA at 6 weeks of age was similar in brain, retina
and liver, with DHA being the main form of labeled FA
whereas in RBC n-3 DPA predominated [22]. Finally, in
rats, RBC n-3 DPA was found to be the most reliable indi-
cator of brain DHA status, more than RBC DHA [11].
Therefore, blood analysis might not reflect the potential
elongation seen in other tissue compartments such as
brain. As further limitation, through this study we were
not able to observe the effects of a formula containing
dairy lipids on brain or retina FA composition.
Even if RBC DHA levels represent an interesting par-
ameter to evaluate the effects of dietary interventions,
they are not always correlated with functional out-
comes. For example, in the DIAMOND study, RBC
DHA was positively correlated with visual acuity but
not with cognitive parameters in term infants [16, 23].
Consequently, it would be interesting to study the ef-
fect of an infant formula containing dairy lipids on
functional outcomes in infants to verify previous results
obtained in animal models.
Conclusions
This study showed that a formula containing dairy
lipid increased RBC total Omega 3 status in healthy
term infants, at levels similar to breastfed babies.
Breast milk remains the optimal food for infants.
However, when breastfeeding is not possible, modify-
ing lipid quality in formula by adding dairy lipids
should be considered as an alternative method to im-
prove infants’ Omega 3 FA status. However, further
investigation would be needed to evaluate the effect
of a dairy lipid-based formula (supplemented or not
with DHA) on functional outcomes such as visual
acuity or cognitive development.
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